Korro Bio, Inc. (KRRO) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Korro Bio, Inc. is a biopharmaceutical company developing genetic medicines based on RNA editing using its proprietary OPERA platform. The company focuses on treating rare and highly prevalent diseases by editing RNA to modify protein function. As of the reporting date, the company has no approved products and has not generated revenue from product sales. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $6.4 million | $2.3 million |
| Net Loss | $(117.3) million | $(83.6) million |
| Research & Development Expenses | $65.6 million | $63.6 million |
| General & Administrative Expenses | $28.2 million | $30.5 million |
| Long-Lived Asset Impairment | $30.9 million | $0 |
| Restructuring Charges | $3.6 million | $0 |
| Cash, Cash Equivalents & Marketable Securities (Dec 31, 2025) | $85.2 million | $126.1 million |
| Accumulated Deficit (Dec 31, 2025) | $(383.8) million | $(266.6) million |
Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product revenue. Debt levels are not explicitly detailed as a line item, but the company relies on equity financing and has operating lease liabilities of approximately $43.5 million.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $33.7 million (40%) year-over-year, driven primarily by a $30.9 million non-cash impairment charge on long-lived assets (operating lease right-of-use assets and property/equipment) and $3.6 million in restructuring charges.
- Program Pivot: In November 2025, the company announced that its Phase 1/2a REWRITE clinical trial for KRRO-110 (AATD) did not reach projected protein levels. Consequently, the program was terminated, and the company pivoted to a next-generation GalNAc-conjugated delivery approach for AATD.
- Collaboration Pause: The research collaboration with Novo Nordisk, which generated $6.4 million in revenue in 2025, entered a 12-month pause in November 2025. No material revenue is expected from this agreement during the hold period.
- Workforce Reductions: The company implemented workforce reductions in May 2025 (approx. 20%) and November 2025 (approx. 34%) to streamline operations and extend its cash runway.
- Capital Raises: Subsequent to the fiscal year end, the company raised approximately $85.0 million in a March 2026 private placement and $5.1 million under its at-the-market offering program in January 2026.
Guidance, Outlook, and Risks
- Development Milestones:
- KRRO-121 (Hyperammonemia): Anticipates a regulatory filing to enable a first-in-human trial in the second half of 2026.
- AATD Program: Expects to nominate a development candidate for the next-generation GalNAc-conjugated program in the second quarter of 2026.
- Cash Runway: Management believes existing cash resources, combined with proceeds from the January 2026 and March 2026 financings, will fund operations into the second half of 2028.
- Key Risks:
- Technology Risk: RNA editing is a novel technology with limited clinical validation; preclinical success does not guarantee clinical success.
- Liquidity Risk: The company has incurred significant losses since inception and will require substantial additional funding. Failure to raise capital could force delays or elimination of programs.
- Collaboration Risk: The pause in the Novo Nordisk collaboration creates uncertainty regarding future revenue and development support for partnered programs.
- Regulatory Risk: Regulators have not established definitive guidelines for RNA editing therapies, creating uncertainty in the approval pathway.
Investor Verification Checklist
- Verify Cash Runway: Confirm the sufficiency of the $85.2 million (year-end) plus subsequent financing proceeds to reach the H2 2026 KRRO-121 filing and H2 2028 milestones without further dilution.
- Assess AATD Pivot Viability: Evaluate the preclinical data supporting the new GalNAc-conjugated AATD candidate compared to the failed LNP-based KRRO-110.
- Monitor Novo Nordisk Status: Track the status of the 12-month pause and the likelihood of resuming the collaboration or securing alternative partners for cardiometabolic targets.
- Review Impairment Details: Analyze the specific assumptions used in the $30.9 million impairment charge to understand the impact on future asset valuations and lease obligations.
- Check Dilution Impact: Review the terms of the March 2026 private placement (including pre-funded warrants) to assess the dilution impact on existing shareholders.